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REGULAR ARTICLE

Sociodemographic factors in patients continuing warfarin vs those
transitioning to direct oral anticoagulants
Jordan K. Schaefer,1 Suman L. Sood,1 Brian Haymart,2 Xiaokui Gu,2 Xiaowen Kong,2 Eva Kline-Rogers,2 Steven Almany,3 Jay Kozlowski,4
Gregory D. Krol,5 Scott Kaatz,5 James B. Froehlich,2 and Geoffrey D. Barnes2
1
Division of Hematology/Oncology and 2Division of Cardiovascular Medicine, Department of Medicine, University of Michigan, Ann Arbor, MI; 3Division of Cardiovascular
Medicine, Department of Internal Medicine, Oakland University William Beaumont School of Medicine, Royal Oak, MI; 4Huron Valley Sinai Hospital, Commerce Township, MI;
and 5Henry Ford Hospital, Detroit, MI

Key Points

• Race, income, and
partnered status were
associated with anticoagulant use but clinical
factors had a stronger
association.

Clinical factors and patient preferences are important for selecting oral anticoagulants for
venous thromboembolism (VTE) and atrial ﬁbrillation (AF). The relative association of
sociodemographic factors with anticoagulant use is unknown. We evaluated a prospective
cohort to compare sociodemographic variables in patients who continued on warfarin for AF
or VTE to those who transitioned to 1 of the direct oral anticoagulants (DOACs). Adult patients,
newly started on warfarin, were enrolled through 6 anticoagulation clinics across Michigan.
Of 8468 patients, 53.3% had AF, 45.6% had VTE, and 1.1% had both. Of these, 696 (8.2%)
switched from warfarin to a DOAC. There were no signiﬁcant differences between
switchers and nonswitchers for percentage of time with a therapeutic international
normalized ratio on warfarin, urban-rural residence status, or health insurance. Switchers
were more often white (83.3% vs 77.7%; P , .001), partnered (67.3% vs 59.2%; P , .001),
or resided in a zip code with a higher median household income (P , .001). The results
show that sociodemographic factors, such as race, partnered status, and income are
associated with a patient’s likelihood of switching to a DOAC vs remaining on warfarin
therapy. Although clinical factors predominate, the reason for, and impact of, these
observed variations in care requires further investigation.

Introduction
The regulatory approval and growing clinical embrace of the direct oral anticoagulants (DOACs:
apixaban, dabigatran, edoxaban, or rivaroxaban), has challenged warfarin as the mainstay of oral
anticoagulation for the treatment of venous thromboembolism (VTE) and stroke prevention in nonvalvular
atrial fibrillation (AF). Although clinical factors, including renal function or comorbidities, are associated
with warfarin vs DOAC use, it is unknown how socioeconomic variables such as income, race, sex,
health insurance, or partnered status may influence anticoagulant use.
A history of labile international normalized ratio (INR) tests among otherwise compliant patients is
hypothesized to affect anticoagulant use, favoring the DOACs, which do not require routine monitoring
or have as many drug or dietary interactions.1 The quality of INR control on warfarin can be reflected by the
percentage of time in the therapeutic range (TTR), a measure associated with morbidity and mortality.2 The
influence of TTR on choice of anticoagulant use has not been well studied. However, studies in AF have shown
that socially disadvantaged patients spend less TTR2 and are at increased risk of bleeding from warfarin.3
We sought to investigate the association between clinical factors, TTR, and sociodemographic variables
with anticoagulant use for patients with AF and/or VTE. We hypothesized that socioeconomically
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advantaged patients (as reflected by insurance status, income, race,
and partnered status) would be more likely to transition from warfarin to
a DOAC. Furthermore, we predicted that patients from rural areas
would be more likely to switch given that monitoring is less accessible.
We also expected that clinical factors, such as renal or hepatic
dysfunction, extreme obesity (body mass index [BMI] . 40),4 a low TTR,
or recent bleeding would be associated with continued warfarin use.

Methods
The study is a retrospective analysis of a prospectively collected
data set. The study included all consecutive, adult patients newly
initiated on warfarin anticoagulation for nonvalvular AF or VTE
recruited through Blue Cross Blue Shield of Michigan’s Anticoagulation Quality Improvement Initiative over the study period.
This collaborative of 6 outpatient anticoagulation clinics throughout
the state of Michigan represents both academic and community
practices that enroll patients with all forms of health insurance.5
Institutional review board approval was obtained through the
University of Michigan, along with an institutional review board–
approved waiver of consent. Patients were enrolled and followed
prospectively from January 2009 to July 2016. The “warfarin” group
consisted of patients treated exclusively with warfarin; those who
transitioned to a DOAC comprised the “DOAC switch” group.
Data were abstracted from enrollment through the end of the study
period or anticoagulant discontinuation by trained data abstractors
with random audits to ensure the accuracy of the data. Collected data
included demographics, comorbid conditions, medications, stroke
and VTE risk factors, creatinine clearance, INR values, and episodes of
hemorrhage, thrombosis, or blood transfusion. TTR was calculated
using Rosendaal linear interpolation.6 A modified Charlson Comorbidity Index7 and HAS-BLED (hypertension, abnormal renal/liver
function, stroke, bleeding history or predisposition, labile INR, elderly,
drugs/alcohol concomitantly) score8 were calculated for each patient.
The primary outcome was anticoagulant status (continue on warfarin
vs switch to DOAC). Independent variables included race, partnered
status, health insurance, income, and household degree of urbanization. Income was derived from the 2014 US Census Bureau’s
American Community Survey9 based on the median income of the
patient’s zip code of residence; the 2010 rural-urban commuting area
codes (RUCAs) were used to determine the degree of urbanization
corresponding to the patient’s zip code of residence.10
The Student t test and Wilcoxon rank-sum test were used for
continuous variables, and x2 and Fisher exact tests were used for
categorical variables. Univariate analyses were performed for each
of the factors felt to a priori potentially influence anticoagulant
selection. We then performed multivariable logistic regression and
reduced the model with only significant variables included. All
authors had access to the primary study data.

Results
A total of 8468 patients met the study inclusion criteria; 53.3%
were anticoagulated for stroke prevention with nonvalvular AF,
45.6% for VTE, and 1.1% for both. Over the study period, 8.2%
switched from warfarin to a DOAC. Given that the DOACs were not
approved until 2010, no patients switched in 2009 and a trivial
number switched in 2010. From 2011 to mid-2016, the rate of
switching averaged 4% (range, 2.2%-5.4%) without a clinically
significant difference by year. The demographics of the warfarin
group were similar to the DOAC switch group with respect to age,
12 DECEMBER 2017 x VOLUME 1, NUMBER 26

sex, and weight (Table 1). The modified Charlson Comorbidity
Index, HAS-BLED scores, and percentage TTR on warfarin were
also comparable between the 2 groups.
The DOAC switch group had a greater representation of patients
with AF (73.3% vs 51.5%, P , .001; Table 1). Accordingly, this
group had more patients with AF risk factors, such as coronary
artery disease, hypertension, prior tobacco use, or heavy alcohol
use. This group was more likely to be on antiplatelet therapy. The
warfarin group was more likely to have a history of bleeding, a
history of VTE, or chronic kidney disease. A greater proportion of
switchers had experienced a new thromboembolic event (3% vs 0.8%,
P , .001) while followed on warfarin. This was true among those
anticoagulated for both VTE (8.9% of switchers vs 1.1% of patients
remaining on warfarin) and AF (1% of switchers vs 4% of patients
remaining on warfarin), however, it was only significantly increased for
VTE (P , .001).
With regard to sociodemographic variables (Table 2), patients
in the DOAC switch group were more often white (83.3% vs
77.7%, P , .001), married/living with a partner (67.3% vs 59.2%,
P , .001), and more often resided in a zip code with a higher
median household income, compared with patients remaining on
warfarin. The degree of urbanization as reflected by RUCA codes
revealed no significant differences between the groups, but over
90% of the study population lived in a metropolitan area.
In multivariable logistic regression analysis, a new thromboembolic
event while on warfarin was the strongest predictor of DOAC
switching status (odds ratio [OR], 7.03; 95% confidence interval
[CI], 3.99-12.37). Patients with higher predicted income showed a
nonsignificant increase in the rate of switching to a DOAC (OR,
1.07; 95% CI, 0.99-1.16), whereas partnered status remained
significant (OR, 1.31; 95% CI, 1.09-1.58) when adjusting for other
factors. Renal insufficiency, having received a blood transfusion,
and VTE as the indication for anticoagulation were all associated
with remaining on warfarin (Figure 1).

Discussion
Our study suggests that sociodemographic factors are associated
with which patients transition from warfarin to DOACs. However,
clinical factors demonstrated a much stronger association. Such
sociodemographic variation raises concerns that patients who are
vulnerable, whether by virtue of race, income, or unpartnered status,
may not have equitable access to the DOACs. Furthermore,
patients who belong to .1 of these groups may face even greater
barriers to the DOACs; further attention to these findings is
warranted. Warfarin management, as reflected by the TTR, was
similar between the 2 groups, suggesting it is not a common
impetus to change anticoagulants.
Socially disadvantaged patients may have more difficulty with INR
monitoring for warfarin due to barriers of cost or transportation;
they otherwise may be lacking in necessary social support or
agency.11-13 Therefore, it could be anticipated that such patients
could benefit from transitioning to 1 of the DOACs. However, the
direct costs of obtaining the DOACs pose a barrier for many of
these patients. Indeed, a large Canadian study suggested that
higher-socioeconomic-status patients with AF were more likely to
switch to dabigatran through private means, until the drug was
publicly available, and this disparity resolved.14 Patients who
identified themselves as married or living with a partner were more
SOCIODEMOGRAPHIC FACTORS IN WARFARIN VS DOACs
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Table 1. Clinical characteristics of patients remaining on warfarin compared with those switching to a DOAC
Warfarin, N 5 7772
Age, mean (SD), y

DOAC switch, N 5 696

P

66 (16)

67 (14)

.24

4003 (51)

378 (54)

.15

Weight, ,50 kg, N (%)

218 (3)

14 (2)

.24

Weight, .120 kg, N (%)

785 (10)

74 (11)

.68

BMI .40, N (%)

816 (11)

74 (11)

.98

Length of treatment, mean (SD), d

470 (589)

406 (495)

,.001

Current tobacco user, N (%)

616 (8)

51 (7)

.57

DVT/PE

3683 (47)

179 (26)

,.001

AF/flutter

4002 (52)

510 (73)

,.001

87 (1)

7 (1)

.78

57 (0.2)

56 (0.2)

.89

Diabetes mellitus

1932 (25)

153 (22)

.09

Coronary artery disease

1975 (25)

205 (30)

.02

Recent myocardial infarction, #6 mo

248 (3)

23 (3)

.87

Remote myocardial infarction, .6 mo

621 (8)

49 (7)

.37

Hypertension

5026 (65)

508 (73)

,.001

Congestive heart failure

1357 (18)

136 (20)

.17

Hypercoagulable state

202 (3)

25 (4)

.14

Liver disease

148 (2)

15 (2)

.64

Male sex, N (%)

Primary indication, N (%)

Both
TTR, % of time (SD)
Comorbidities, N (%)

Chronic kidney disease

1009 (13)

45 (7)

,.001

Cancer

1630 (21)

129 (19)

.13

Prior stroke or transient ischemic attack

850 (11)

91 (13)

.09

Prior gastrointestinal bleed

356 (5)

22 (3)

.08

Prior DVT/PE

1197 (15)

85 (12)

.02

Any recent bleeding, #30 d

150 (2)

17 (2)

.35

Any remote bleeding, .30 d

166 (2)

7 (1)

.04

54 (1)

3 (0)

.63

Bleeding diathesis
History of embolism, not DVT/PE
Heavy alcohol or drug use
Former tobacco use

50 (1)

6 (1)

.46

371 (5)

46 (7)

.03

2281 (29)

239 (34)

.006

Falls

223 (3)

13 (2)

.12

Seizure disorder

101 (1)

12 (2)

.35

Peripheral arterial disease

414 (5)

37 (5)

.99

Chemotherapy

174 (2)

18 (3)

.56

HAS-BLED, score (SD)

2.4 (1.4)

2.5 (1.3)

.6

Modified Charlson Comorbidity Index, score (SD)

4.3 (2.2)

4.3 (1)

.33

Antiplatelet medications, N (%)
Aspirin (any dose)

3093 (40)

311 (45)

.01

NSAIDs

327 (4)

35 (5)

.3

Clopidogrel, ticlopidine

411 (5)

47 (7)

.1

Prasugrel, ticagrelor or other antiplatelet

25 (0.3)

2 (0.3)

.88

One antiplatelet agent

2927 (38)

294 (42)

.02

.1 antiplatelet agent

307 (4)

34 (5)

.23

DVT, deep vein thrombosis; PE, pulmonary embolism; SD, standard deviation.
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Table 2. Comparison of socioeconomic variables between patients
remaining on warfarin and those transitioning to a DOAC
Warfarin,
N 5 7772

DOAC switch,
N 5 696

P

First quartile (lowest)

$34 757

$36 404

,.001

Second quartile

$51 265

$51 443

Third quartile

$65 338

$65 626

Fourth quartile (highest)

$90 609

$93 152

4562 (59)

465 (67)

,.001

,.001

Median income, USD

Partnered status, N (%)
Married/living with partner
Race, N (%)
White

5986 (78)

574 (83)

Black

1136 (15)

47 (7)

Other

585 (8)

68 (10)

Medicare

3973 (52)

388 (57)

Commercial

3345 (44)

275 (40)

Medicaid

237 (3)

20 (3)

Uninsured

64 (1)

2 (0)

6383 (82)

571 (82)

884 (11)

75 (11)

Insurance, N (%)
.08

RUCA code,* N (%)
Metropolitan area: 1
Metropolitan area: 2-3
Micropolitan area: 4-6

235 (3)

20 (3)

Small town: 7-9

112 (1)

12 (2)

Rural area: 10

155 (2)

17 (2)

21 (0)

1 (0)

Other: 11

.78

RUCA, rural-urban commuting area code; USD, US dollar.
*Per the United States Department of Agriculture Economic Research Service.10

likely to transition to a DOAC. Although there could be social reasons
to explain this finding, it is likely also a reflection of income.15
Partnered status was a question asked directly in this study whereas
income was approximated, which likely explains our findings.
Interestingly, health insurance type was not associated with who
transitioned to a DOAC. In our clinical experience, many of our
insured patients have comparable copays with the DOACs and

warfarin; uninsured patients are often able to access DOACs through
prescription assistance programs. Therefore, providers should be
cautious not to assume that insurance status precludes DOAC use
for an appropriately selected patient without fully exploring this option.
Although informative on how sociodemographic factors could relate
to anticoagulant use, the data are intriguing on how DOACs are
being used clinically for AF and VTE. For example, recent guidance
advocates not using DOACs for VTE in patients with a BMI . 40 kg m22
given the paucity of data in this population.4 Despite this, 11% of
switchers had BMIs in this range, similar to the number observed in the
warfarin group. Patients with chronic kidney disease more commonly
stayed on warfarin (13.0% vs 6.5%; P , .001). This is likely
appropriate due to the pharmacokinetics of DOACs and the limited
data available for DOACs in this population. Although our analysis did
not assess DOAC use by the degree of renal impairment, it does
show that the drugs are being used for this group. Both groups had
;2% of patients identified as having chronic liver disease. This is
again a population where there are limited data to support the use of
the DOACs, and caution is necessary. Further research is needed to
better understand both safety and efficacy outcomes for these
special populations being treated with DOACs.
We observed that patients with AF were more likely to switch to
a DOAC than patients with VTE. This could be related to the
difference in anticoagulation duration between the 2 groups.
Patients with AF will often be on long-term anticoagulation and
thus may be more inclined to change therapies. Our study included
patients on short-term anticoagulation for VTE, who may be less
likely to change anticoagulants once started on warfarin. Another
contributor may be that patients with AF are often being managed
by specialists compared with VTE, which may be managed by
primary care providers. Specialists may have different prescribing
patterns compared with general practitioners. It is also noteworthy
that DOACs were approved for stroke prevention for AF starting in
2010, years prior to their respective approvals for the treatment and
prevention of VTE starting in 2012. Patients with AF and their
providers thus had more time to consider switching anticoagulants,
potentially contributing to the increased proportion of AF patients
who switched anticoagulants in our study.
Patients remaining on warfarin were more likely to have a history
of bleeding (2.1% vs 1%; P 5 .04). This is likely related to the
potential to reverse warfarin-based anticoagulant effects with
clotting factors, vitamin K, or plasma. As antidotes to DOACs

New thrombosis

Figure 1. Patient factors associated with warfarin to

OR

LCL

UCL

7.36

4.17

13.0
3.09

Chemotherapy

1.81

1.07

Prior CVA/TIA

1.36

1.05

1.75

Partnered status

1.31

1.09

1.58

Median income group

1.07

0.99

1.16

Renal insufficiency

0.55

0.44

0.68

Indication: VTE

0.36

0.30

0.44

RBC transfusion

0.32

0.14

0.69

DOAC switch: OR and 95% CI. CVA, cerebrovascular
accident; LCL, lower control limit; RBC, red blood cell;

Warfarin
0.1

DOAC switch
1

10

TIA, transient ischemic attack; UCL, upper control limit.
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become more widely available, it is possible that this difference in
practice patterns will change. The warfarin group also had a slightly
higher percentage of patients with a history of VTE (15.4% vs
12.2%; P 5 .02). The reason for this observation is not clear but
could reflect the time frame of DOAC approval for VTE relative to
the study, a patient preference for an agent they may have been
treated with in the past successfully, or a clinician desire for an
agent that can be monitored, especially if there were concerns for
noncompliance.
Strengths of the study include the large size and prospective followup. Limitations of this study include limited geographical area, with a
mostly metropolitan (.90%) population. Our measure of income was
approximated based on zip code of residence, and there was a low
number of uninsured or Medicaid patients. The study may have
insufficient statistical power to determine differences in anticoagulant
use for these insurance statuses and based on degree of
urbanization. The study did not include patients started directly on
DOACs, and there could be selection bias among those patients
started on warfarin. However, many patients were enrolled prior to
DOACs becoming commercially available. All patients were also
followed at anticoagulation centers, where referral patterns or
management practices could affect the results. Additionally, anticoagulation clinics may favor warfarin relative to DOACs, given that
DOACs may not require the services they provide.
In conclusion, sociodemographic variables may influence which
patients transition from warfarin to a DOAC for AF or VTE, but clinical
factors predominate. Further research is needed to understand the
reason for these variations in care.
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